Company / SG&A Expense
BioAge Labs, Inc. SG&A Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$27.8M
FY2025
5-year range
$14.5M / $27.8M
FY2023-FY2025
Trend
+45.2%
vs FY2024
Sector context
#190 of 213
Health Care
What the data says
BioAge Labs, Inc.'s sg&a expense of $28M is lower than 89% of companies in the Health Care sector (FY2025). Increased from $15M to $28M over the past 2 years.
Based on SEC 10-K filings.
$28M in FY2025.
Increased from $15M to $28M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 213This company $27.8M Sector average $722.3M
▼
-96.2% below sector average
Key checks
Key Insights
- In FY2025, sg&a expense increased 45.2% year-over-year.
- Ranks #190 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.75 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.8M | +45.2% |
| FY2024 | $19.2M | +32.0% |
| FY2023 | $14.5M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026